Gerresheimer calls a halt to discussions on potential takeover

German medical equipment and packaging maker Gerresheimer (GXIG.DE) has terminated takeover discussions, ongoing since early 2025 with potential buyers including KPS Capital Partners and Warburg Pincus, stating the continuation was not in the best interest of the company and stakeholders, leading to a 6% share decline. This decision follows a recent cut to its 2025 revenue growth forecast to 0-2% due to weak demand in cosmetics and oral liquids, despite its notable production of pens for weight-loss medications like Wegovy. The company, however, maintains a medium-term outlook of 6-9% organic revenue growth and 23-25% organic adjusted EBITDA margin, and plans a strategic review of its moulded glass business on October 15.

Analysis

Gerresheimer's decision to halt discussions on a potential sale has removed the M&A premium from its valuation, triggering an immediate 6% decline in its shares. This move forces a re-evaluation of the company on its standalone fundamentals, which present a mixed picture. The company is currently navigating near-term headwinds, evidenced by its recent reduction of the 2025 revenue growth forecast to a range of 0-2%, citing weak demand in its cosmetics and oral liquids segments. However, this short-term softness is contrasted by a robust medium-term outlook, with management projecting 6-9% organic revenue growth and an adjusted EBITDA margin of 23-25%. This optimism is likely anchored in high-growth areas, such as its production of injection pens for popular weight-loss medications like Wegovy. A key upcoming catalyst is the strategic review of its moulded glass business on October 15, which could result in a spin-off aimed at unlocking shareholder value and streamlining operations.

Key Decisions for Investors

• Given the termination of takeover talks and recent downward revenue guidance revision, investors should anticipate potential continued share price volatility in the near term.
• The strategic review of the moulded glass business on October 15 represents a significant catalyst, and its outcome, particularly a potential spin-off, could materially impact the company's valuation.
• Long-term investors should assess if the growth potential from supplying the weight-loss drug market can outweigh the current cyclical weakness in its cosmetics and oral liquids businesses to justify the company's standalone medium-term growth targets.